Loading...
XLON
CREO
Market cap85mUSD
Jul 10, Last price  
14.25GBP
1D
0.00%
1Q
21.28%
Jan 2017
-82.49%
IPO
-82.16%
Name

Creo Medical Group PLC

Chart & Performance

D1W1MN
XLON:CREO chart
P/E
12.08
P/S
10.67
EPS
0.01
Div Yield, %
Shrs. gr., 5y
20.61%
Rev. gr., 5y
-8.64%
Revenues
6m
+50.00%
802,4830534,67000013,4739,429,00025,161,00027,169,00030,800,0004,000,0006,000,000
Net income
5m
P
-1,696,670-2,382,010-3,329,590-7,765,517-8,408,598-9,872,306-15,911,150-20,316,000-24,595,000-26,936,000-21,700,000-28,700,0005,300,000
CFO
-19m
L-16.22%
-1,361,368-2,274,980-3,125,676-6,914,766-6,995,690-14,195,394-11,540,996-16,085,000-25,980,000-24,988,000-21,600,000-22,200,000-18,600,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquartered in Chepstow, the company's core offering is Croma, an advanced energy platform. This platform is engineered to power a diverse collection of multi-modal instruments, thereby enhancing therapeutic interventions for both medical professionals and patients. Its extensive product portfolio includes specialized tools such as Speedboat Inject, an adaptable energy instrument designed for flexible endoscopic procedures; Speedboat Slim, a flexible bipolar radiofrequency (RF) and microwave device for precise tissue cutting and coagulation; MicroBlate Fine, a microwave needle for ablation; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device engineered to control upper and lower gastrointestinal bleeds; and SpydrBlade Flex, a flexible scissor-like instrument that integrates bipolar RF and microwave technology to grasp, cut, and coagulate highly vascularized tissues.
IPO date
Dec 09, 2016
Employees
284
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT